Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dendritic cells and macrophages are professional antigen-presenting cells (APCs) that serve as critical bridges between innate and adaptive immunity. Macrophages are primarily involved in phagocytosis, tissue repair, and maintaining homeostasis, while dendritic cells are specialized in capturing antigens and migrating to lymph nodes to prime T cell responses. In the tumor microenvironment, these cells can adopt either pro-inflammatory (antitumor) or immunosuppressive (pro-tumor) phenotypes, making them key targets for immunotherapy. Drugs targeting these cells often aim to reprogram their functional state, such as using Toll-like receptor (TLR) agonists to promote maturation or blocking inhibitory receptors to restore their ability to activate T cells. Their plasticity and central role in immune regulation make them pivotal in treating cancer, chronic infections, and autoimmune disorders.
Modulation of immune response through activation or inhibition of cell-surface receptors (e.g., TLRs, Fc receptors) and signaling pathways (e.g., mTOR) to enhance antigen presentation or reduce immunosuppression.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dendritic cells and macrophages (DC/Mφ).